Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASE Technology Holding Co Ltd (ASX) vs Quest Diagnostics Inc (DGX) Price & Performance

ASE Technology Holding Co Ltd
Quest Diagnostics Inc

Price performance

Price movement over the last 24 hours

Key statistics

ASE Technology Holding Co Ltd vs Quest Diagnostics Inc — how do they compare? ASE Technology Holding Co Ltd trades at $41.71 (market cap $92.88B), while Quest Diagnostics Inc trades at $207.44 (market cap $22.96B). The key difference: ASE Technology Holding Co Ltd is far larger — about 4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.66%). Which is the better fit depends on your goals.

ASXDGX
Market Cap
$92.88B$22.96B
Sector
TechnologyHealth
52-Week High
$45.12$216.02
52-Week Low
$9.50$166.42
Enterprise Value
$97.32B$28.98B
Dividend Yield
0.98%1.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASE Technology Holding Co Ltd

ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.

Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.

DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASE Technology Holding Co Ltd

ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.

Read more on ASX

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX